The revenue for the cell therapy Carvykti and the EGFR-targeted lung cancer duo Rybrevant-Lazcluze contributed to double digit gains in oncology drug sales.

The company hopes to commercialize its tumor profiling assay after it secures $10 million via a share purchase agreement.

The privately funded basket trial makes good on its aim to enroll underrepresented groups amid a DEI-hostile federal funding ...

The participating regions are home to 84 percent of sickle cell Medicaid patients who could gain access to gene therapies under outcomes-based agreements.

Debiopharm will take over development of the PKMYT1 inhibitor and advance it in combination with its WEE1 inhibitor in the MYTHIC trial.

The company, which spun out of a Korean institute, said its test has been listed at 10 leading hospitals and academic centers.

While NICE recommended the drug for patients with at least one F508del mutation, Vertex struck a reimbursement deal with NHS England for a broader population.

A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

The firm also said it would evaluate strategic alternatives for its animal health business and close a prostate cancer vaccine trial.

The biotech will add a pivotal Phase III cohort to its ongoing Phase I/II trial evaluating ATSN-201 in X-linked retinoschisis ...

The firm said the agency cited chemistry, manufacturing, and controls issues in its complete response letter, but had no concerns about product quality.

An AI-based EGFR biomarker tool could preclude the need for a rapid PCR test in nearly half of advanced lung adenocarcinoma cases, a study has suggested.